DB12117InvestigationalSmall molecule
Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others. Mitometh has been investigated... Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor.
- Formula / weight
- C15H12Cl4 · 334.06 g/mol (avg)
Resolves to
Structure
InChIKey
MOTIYCLHZZLHHQ-UHFFFAOYSA-NSMILESCC(Cl)(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1ClTransporters
What you can answer from here — as of July 07, 2026
3TransportersSubstrate / inhibitor direction, not just membershipListed above
Which companies are running trials of Mitometh, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account